BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19628770)

  • 1. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
    Hou JM; Greystoke A; Lancashire L; Cummings J; Ward T; Board R; Amir E; Hughes S; Krebs M; Hughes A; Ranson M; Lorigan P; Dive C; Blackhall FH
    Am J Pathol; 2009 Aug; 175(2):808-16. PubMed ID: 19628770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
    Messaritakis I; Politaki E; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Kallergi G; Souglakos J; Georgoulias V
    PLoS One; 2017; 12(7):e0181211. PubMed ID: 28719656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.
    Messaritakis I; Politaki E; Koinis F; Stoltidis D; Apostolaki S; Plataki M; Dermitzaki EK; Georgoulias V; Kotsakis A
    Sci Rep; 2018 Feb; 8(1):2238. PubMed ID: 29396560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
    Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
    J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Aggarwal C; Wang X; Ranganathan A; Torigian D; Troxel A; Evans T; Cohen RB; Vaidya B; Rao C; Connelly M; Vachani A; Langer C; Albelda S
    Lung Cancer; 2017 Oct; 112():118-125. PubMed ID: 29191584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
    de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
    Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.
    Hiltermann TJN; Pore MM; van den Berg A; Timens W; Boezen HM; Liesker JJW; Schouwink JH; Wijnands WJA; Kerner GSMA; Kruyt FAE; Tissing H; Tibbe AGJ; Terstappen LWMM; Groen HJM
    Ann Oncol; 2012 Nov; 23(11):2937-2942. PubMed ID: 22689177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
    Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
    Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
    Dean EJ; Cummings J; Roulston A; Berger M; Ranson M; Blackhall F; Dive C
    Neoplasia; 2011 Apr; 13(4):339-47. PubMed ID: 21472138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.
    Micha D; Cummings J; Shoemaker A; Elmore S; Foster K; Greaves M; Ward T; Rosenberg S; Dive C; Simpson K
    Clin Cancer Res; 2008 Nov; 14(22):7304-10. PubMed ID: 19010845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).
    Messaritakis I; Stoltidis D; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Politaki E; Apostolaki S; Souglakos J; Georgoulias V
    Sci Rep; 2017 Mar; 7():45351. PubMed ID: 28349943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Messaritakis I; Politaki E; Plataki M; Karavassilis V; Kentepozidis N; Koinis F; Samantas E; Georgoulias V; Kotsakis A
    Lung Cancer; 2017 Feb; 104():16-23. PubMed ID: 28212995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.
    Normanno N; Rossi A; Morabito A; Signoriello S; Bevilacqua S; Di Maio M; Costanzo R; De Luca A; Montanino A; Gridelli C; Rocco G; Perrone F; Gallo C
    Lung Cancer; 2014 Aug; 85(2):314-9. PubMed ID: 24882383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
    Wu C; Hao H; Li L; Zhou X; Guo Z; Zhang L; Zhang X; Zhong W; Guo H; Bremner RM; Lin P
    J Thorac Oncol; 2009 Jan; 4(1):30-6. PubMed ID: 19096303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.
    Chu T; Jiang L; Ying W; Han B
    Clin Transl Oncol; 2017 Mar; 19(3):326-331. PubMed ID: 27468866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating biomarkers in hepatocellular carcinoma.
    Morris KL; Tugwood JD; Khoja L; Lancashire M; Sloane R; Burt D; Shenjere P; Zhou C; Hodgson C; Ohtomo T; Katoh A; Ishiguro T; Valle JW; Dive C
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):323-32. PubMed ID: 24923562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer.
    Chudziak J; Burt DJ; Mohan S; Rothwell DG; Mesquita B; Antonello J; Dalby S; Ayub M; Priest L; Carter L; Krebs MG; Blackhall F; Dive C; Brady G
    Analyst; 2016 Jan; 141(2):669-78. PubMed ID: 26605519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
    Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
    J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.